Skip to main content

Table 3 Nucleoside RT inhibitor (NRTI) resistance mutations: percentages occurrence in patients treated with duo nucleoside RT inhibitor plus NRTI first -line

From: HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya

ARV regimens n/60 NAMs nucleoside analogue mutations Thymidine analogue mutations
    K65R 184 V T215Y K70R
NNRTI NRTI   R Y/M T/Y R
    n (%) n (%) n (%) n (%)
Efavenz (EFV) containing regiments      
EFV TDF/3TC 3 1 (11.1) 1 (33.3) - 1 (33.3)
  AZT/3TC 15 - 5 (33.3) 1 (6.7) 1 (6.7)
Total   18 1 (5.6) 6 (33.3) 1 (5.6) 2 (11.1)
Nevirapine (NVP) containing regiments      
NVP D4T/3TC 4 - 2 (50) - 1 (9.1)
  TDF/3TC 3 1 (10) 1 (10) -  
  AZT/3TC 18 - 3 (12.5) 2 (8.3) -
Totals   25 1 (3.8) 6 (24) 2 (7.7) 1 (3.8)
PI       
Lopinavir (LPV)/Ritinovir containing regiments      
LPV/R ABC/DDI 1 - - - -
  ABC/3TC 2 - - - -
  AZT/3TC 7 - - -  
  AZT/DDI 5 - - - -
  TDF/ABC 2 - - 2 (100) -
  AZT/TDF/3TC 1 - - - -
Sub Total   18 - 1 (5) 2 (10) -
Totals   60 2 (4.7) 13 (21.7) 5 (7.8) 3 (4.7)